What are Inherited Colorectal Cancer Syndromes?
Colorectal cancer is one of the most common cancers in Australia. About 30% of people with colorectal cancer have a family history of the disease, and up to 10% have genetic changes linked to inherited cancer syndromes like Lynch syndrome and Familial Adenomatous Polyposis (FAP) or MUTYH-Associated Polyposis (MAP).
Our Inherited Colorectal Cancer Syndrome tests
Lynch Syndrome Panel
Lynch syndrome is a common inherited condition that increases the risk of colorectal cancer, endometrial cancer, and other cancers. It is caused by specific changes in certain genes (MLH1, MSH2, MSH6, PMS2, and EPCAM).
Genetic testing can identify these changes, allowing patients and their families to take steps to reduce their cancer risk through regular screening and preventive measures.
FAP/MAP Panel
This test looks for genetic changes linked to Familial Adenomatous Polyposis (FAP) and MUTYH-Associated Polyposis (MAP), which are conditions that increase the risk of developing colorectal cancer.
- FAP is a condition where hundreds to thousands of polyps (growths) form in the digestive tract, often leading to cancer before age 40 if not treated. FAP is usually caused by changes in the APC gene, and in about one-third of cases, it happens without a family history of the disease.
- MAP is similar to FAP but is caused by changes in the MUTYH gene and is inherited differently. People with MAP also develop multiple polyps, which again significantly increases the risk of developing colorectal cancer.
Identifying these pathogenic variants early allows for proactive management, including enhanced screening, preventive surgeries, and other risk-reducing strategies.
Why Get Tested?
When there is a family history, both the Lynch Syndrome and FAP/MAP Panels can help in assessing your inherited colorectal cancer risk. Knowing your genetic status allows for earlier, more personalised interventions, potentially preventing cancer or catching it early when it's easier to treat.
Your doctor will be able to advise if you are eligible for Medicare or not. Pre-test genetic counselling is required prior to undertaking genetic testing.
Patients' process
Step 1
Your doctor will discuss your family history with you, and whether testing for inherited colorectal cancer syndromes could be useful. They will complete a dedicated request form and provide pre-test genetic counselling, which you will need to sign that you have received.
Step 2
Medicare may not cover the cost of this test. If you will need to pay for your test, do so here prior to having your blood taken at a local Healius Pathology collection centre. Write your receipt number on the request form.
Step 3
Your results will be delivered to your doctor within 4 - 5 weeks of your sample arriving at the laboratory.
FAQ
Genomic testing in breast and ovarian cancer can be clinically useful in two main areas:
- Diagnostic testing for individuals with a diagnosis or personal history of cancer, to help guide treatment and medical management
- Predictive testing for people without cancer, to determine their future cancer risk, usually when there is a family history of cancer, and especially if a known gene change runs in the family. This may guide medical management to reduce cancer risk.
Understanding inherited cancer risks can help shape medical care for both you and your family.
Genetic counselling involves discussing benefits,limitations and the possible implications of genetic testing. It must becompleted before testing, either with your referring specialist or a qualifiedgenetic counsellor.
Because genetic results can have medical andemotional impacts on both you and your family, national regulations requirecounselling before testing. After counselling, you’ll need to provide informedconsent before proceeding. If you choose not to proceed, you can stop theprocess at this stage.
The BRAoVO panel looks at 13 high and moderate high-risk genes linked to an increased lifetime risk of breast and ovarian cancers, as well as other cancers such as prostate and pancreatic cancer. This includes the well-known BRCA1 and BRCA2 genes.
The BRAoVO Plus panel expands the analysis to 18 genes, which may be particularly relevant for:
- ovarian cancer patients
- breast cancer patients with a family history that includes ovarian cancer
- families with a mix of cancers, including breast, ovarian and colorectal cancer.
If a specific genetic variant has already been identified in your family, you can choose single variant testing instead of a full panel.
Your results will be sent to your clinician orgenetic counsellor, who will discuss them with you along with the next steps.Possible findings include:
Positive result– also known as ‘Pathogenic variant detected’. This means a gene change wasidentified that is known to increase your cancer risk. It does not mean youwill develop cancer but it may impact your medical management. The result can beshared with your relatives who may then consider testing.
Negative result– also known as ‘No pathogenic variant detected’. This means you do not have aharmful change in any of the genes tested. However, this does not eliminate allcancer risk, as other genetic and non-genetic factors can contribute.
Variant of unknown significance (VUS)detected – this means a gene change was identified however its impact onhereditary cancer risk is not yet understood. This finding will not change yourongoing medical care.
Testing for multiple genes takesapproximately 4 weeks. Testing will only begin once you have completed your pre-testgenetic counselling session.
You may change your mind abouttesting at any stage during the process. If you have paid privately for a testbut decide not to proceed, you may be eligible for a partial refund. Administrative costs may apply.
- Medicare covers the test in many cases, but you must be referred by a specialist and meet specific eligibility criteria. Your doctor will confirm if you qualify.
- Private health insurance does not cover genetic testing.
Please call our Customer Care team on 1800 822 999 to discuss a refund if you do not proceed with testing. Administrative costs may apply.
Resources
Why screen patients for inherited colorectal cancer syndromes?
Colorectal cancer is the third most common type of newly diagnosed cancer in Australia. It is estimated that 30% of patients with colorectal cancer have a family history of the disease, and up to 10% have genomic variants associated with inherited cancer syndromes including Lynch syndrome and familial adenomatous syndromes FAP and MAP.
MBS rebated diagnostic and predictive testing for the genes associated with these syndromes is now available for patients who meet criteria and when requested by a specialist medical practitioner. Guidelines recommend anyone with a Lynch syndrome risk of ≥5% as calculated by risk prediction models have germline testing however, MBS guidelines require a risk of ≥10%.
When is testing useful?
Detection of pathogenic variants in genes associated with inherited colorectal cancer syndromes:
• confirms a diagnosis in patients with a personal history of cancer
• provides genotype-specific information on lifetime risk of cancers
• directs patient management, including surveillance and consideration of prophylactic surgery, based on genotype-specific risks
• guides testing of at-risk (asymptomatic) family members
Our panels
Lynch syndrome is one of the most common cancer predisposition syndromes, and confers a significantly increased lifetime risk of colorectal cancer, endometrial cancer and multiple other cancers. A diagnosis of Lynch Syndrome is confirmed by the detection of a pathogenic germline variant in one of the MMR genes (MLH1, MSH2, MSH6 and PMS2) or the EPCAM gene. These are found in our Lynch syndrome panel.
Familial adenomatous polyposis is an autosomal dominant disorder characterised by numerous (>100 to 1000s) gastrointestinal adenomatous polyps that almost inevitably progress to CRC by age 40. A variant of the disorder, attenuated FAP, has a later onset, fewer polyps (usually <100) and reduced occurrence of extra-intestinal manifestations. Both forms of FAP are caused by pathogenic variants of the APC gene. Up to one third of cases are due to de novo (new) variants and therefore have no family history of disease.
MUTYH-associated polyposis is an autosomal recessive disorder characterized by attenuated adenomatous colorectal polyposis (usually 15-100 polyps) and significantly increased lifetime risk of colorectal cancer. MAP is caused by biallelic pathogenic variants of the MUTYH gene.
The APC and MUTYH genes are both found in our FAP/MAP panel.
Steps
Step 1
Discuss your patient’s family history of cancer with them and whether testing for inherited colorectal cancer syndromes would be beneficial. Complete a dedicated request form and pre-test genetic counselling, ensuring the patient signs the form once completed.
Step 2
Patients who are not covered by Medicare will need to prepay for the test here and note their receipt number of the request form. They then attend their most convenient collection centre with their signed request form.
Step 3
Results are delivered to you by your preferred method approximately 4 weeks after the patient has their blood collected.
FAQ
Genetic testing for inherited cancer is a complex process that generates results that can have significant medical and psychological implications for patients and their families. As part of our laboratory accreditation, Genomic Diagnostics must ensure that patients receive appropriate genetic counselling for this type of testing.
Genetic counselling involves discussing benefits, limitations and the possible consequences of the genetic testing to be performed. It can be provided by a specialist or a qualified genetic counsellor and must be undertaken before the patient undergoes testing.
Strategies to identify individuals at risk of Lynch syndrome or individuals who should have germline testing for Lynch syndrome have evolved over time. Prediction models are evidence-based tools that use personal and family history to determine the risk that an individual is a carrier of a pathogenic variant in a gene associated with Lynch syndrome.
The models available for Lynch syndrome are:
- PREMM5 – from Presbyterian Hospital/Columbia University Medical Centre, USA - https://premm.dfci.harvard.edu/
- MMR Pro – from Dept. of Environmental Health Sciences & Dept. of Biostatistics, John Hopkins Bloomberg School of Public Health, USA
- MMR Predict – from Colon Cancer Genetics Group, School of Molecular & Clinical Medicine, University of Edinburgh, UK
The Medicare schedule currently contains three item numbers relevant to inherited colorectal cancer syndromes.
These are only rebatable if requested through a specialist and if the patient meets the criteria set out in them.
In summary:
MBS #73354 – diagnostic testing for Lynch syndrome in individuals with colorectal or endometrial cancer. In colorectal cancer, the patient must have demonstrated loss by IHC of MMR protein in solid tumour tissue. In endometrial cancer, the patient must be at a risk of >10% of having Lynch syndrome.
MBS # 73355 – diagnostic testing for individuals with FAP/MAP where the patient is assessed as being at a risk of >10% of having FAP or MAP.
MBS #73357 – predictive familial cancer test for a single gene variant where a family member has been identified as having this variant. A report from the family member stating the exact details of the variant must be supplied.